$349 Million is the total value of Vida Ventures Advisors, LLC's 8 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CNTA | Centessa Pharmaceuticals plcordinary shares | $65,661,000 | -24.8% | 3,931,818 | 0.0% | 18.81% | -14.1% | |
KNTE | Kinnate Biopharma, Inc. | $63,246,000 | -1.1% | 2,747,433 | 0.0% | 18.11% | +13.0% | |
KRON | Kronos Bio, Inc. | $57,961,000 | -12.5% | 2,765,314 | 0.0% | 16.60% | -0.0% | |
PRAX | Praxis Precision Medicines, Inc. | $54,348,000 | +1.1% | 2,939,329 | 0.0% | 15.57% | +15.5% | |
DYN | Dyne Therapeutics, Inc. | $48,071,000 | -22.8% | 2,960,046 | 0.0% | 13.77% | -11.8% | |
ALLO | Allogene Therapeutics, Inc. | $46,213,000 | -1.5% | 1,798,163 | 0.0% | 13.24% | +12.6% | |
FIXX | Homology Medicines, Inc. | $6,067,000 | +8.3% | 770,845 | 0.0% | 1.74% | +23.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Dyne Therapeutics, Inc. | 14 | Q4 2023 | 37.4% |
Allogene Therapeutics, Inc. | 14 | Q4 2023 | 42.5% |
Kinnate Biopharma, Inc. | 13 | Q4 2023 | 29.3% |
Kronos Bio, Inc. | 13 | Q4 2023 | 20.4% |
Praxis Precision Medicines, Inc. | 12 | Q3 2023 | 33.2% |
Centessa Pharmaceuticals plc | 11 | Q4 2023 | 39.4% |
LianBio | 9 | Q4 2023 | 12.1% |
Homology Medicines, Inc. | 9 | Q3 2022 | 5.2% |
Oyster Pt Pharma Inc | 5 | Q3 2021 | 10.3% |
Assembly Biosciences, Inc. | 4 | Q2 2021 | 4.6% |
View Vida Ventures Advisors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-12 |
13F-HR | 2024-01-05 |
13F-HR | 2023-10-03 |
13F-HR | 2023-07-19 |
13F-HR | 2023-04-13 |
13F-HR | 2023-02-08 |
13F-HR | 2022-10-05 |
13F-HR | 2022-07-15 |
13F-HR | 2022-05-04 |
13F-HR | 2022-02-10 |
View Vida Ventures Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.